Application of synthetic gene circuits to novel NK cell immunotherapy

EPSRC · United Kingdom government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

September 29, 2026
Response Due
Active
Status

Opportunity Overview

We propose to use synthetic biology principles to develop a next-generation therapeutic approach for cancer, in particular carcinomas and focussing on Ovarian Cancer (OC) for our proof-of-principle work. Several different forms of immunotherapy including CAR-T cells and Checkpoint Inhibitors have had important success treating cancer. However, these approaches have had little or no therapeutic benefit for OC due to lack of tumour-antigen availability, T-cell exhaustion or major safety issues e.g. cytokine storms and autoimmune responses. Access is also limited by their cost and complexity. Here we aim to develop a universal platform for cancer immunotherapy based on Natural Killer (NK) cells. This will be based on a universal platform to lower cost and increase accessibility, whilst targeting the currently poor outcomes for OC.

We will enhance and modify an existing gene circuit model to be deployed as a novel immunotherapy via NK cell activation, which can directly kill tumour cells. The circuit will trigger tumour cell-specific expression of molecules that can enhance the activation of endogenous Natural Killer (NK) cells within the tumour or attract more NK cells into the tumour. NK cells play a key role in early tumour clearance without requiring pre-existing immunity or tumour-antigen targeting. The clinical potential for NK cell therapy has already been demonstrated, (Shimasaki et al. Nature Reviews Drug Discovery 2020) without toxicity or need for logistically challenging and expensive autologous production, as in the case of CAR-T cell therapy.

We will develop an adaptable RNA-mediated genetic logic circuit based on that previously described in Nissim et al., 2017. The key component of this genetic circuit is a Boolean AND gate that generates an output signal only if both input signals are present together. The genetic circuit is transferred by viral vectors into cancer cells, in the first case to be tested, ovarian cancer cells. Only a small proportion...

This is one of 98 active United Kingdom Software Development opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyEPSRC
CountryUnited Kingdom
CategorySoftware Development
PublishedSeptember 30, 2022
Procurement stageActive solicitation
Response dueSeptember 29, 2026
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Related Opportunities in United Kingdom

Software Value Added Re-seller Services Framework Pin-RFI
Working Age Services Project Zora - Application Decomposition & Microservices Transition
IBM Enterprise Software and Services Offering (ESSO)
CLI-FTS-59480 PoCT INR Testing Managed Service and Clinical Decision Support Software
Network Planning, Bus Optimisation and Timetabling Decision Support Software
Provision of IT Goods & Software Licenses for WM Trains Ltd
Mobilising On-Call Availability Software
Better Health Mobile App Development Partner

See every United Kingdom Software Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Software Development intelligence report in your inbox

A personalized report on United Kingdom Software Development opportunities, emailed in 5-10 minutes. One per month, no account needed.